<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2019-2-26-31</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-776</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CHRONIC HEART FAILURE</subject></subj-group></article-categories><title-group><article-title>Выявление латентных нарушений углеводного обмена во взаимосвязи с нейрогормональным статусом у госпитализированных больных с хронической сердечной недостаточностью ишемической этиологии</article-title><trans-title-group xml:lang="en"><trans-title>Identification of latent disorders of carbohydrate metabolism in conjunction with neurohormonal status in hospitalized patients with chronic heart failure of ischemic etiology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6511-8534</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Норузбаева</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Noruzbaeva</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Норузбаева Айгуль Мукашевна — доктор медицинских наук, профессор, заведующий отделением хронической сердечной недостаточности.</p><p>Бишкек</p><p>SPIN-код 9534-54-56</p></bio><bio xml:lang="en"><p>Bishkek</p></bio><email xlink:type="simple">noruzbaeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8685-8387</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курманбекова</surname><given-names>Б. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurmanbekova</surname><given-names>B. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Курманбекова Бермет Темирбековна — младший научный сотрудник отделения хронической сердечной недостаточности.</p><p>Бишкек</p><p>Spin-код 5406-4499</p></bio><bio xml:lang="en"><p>Bishkek</p></bio><email xlink:type="simple">bermet101191@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7486-8289</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Османкулова</surname><given-names>Г. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Osmankulova</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Османкулова Гузялия Эльдаровна — научный сотрудник отделения хронической сердечной недостаточности, кандидат медицинских наук.</p><p>Бишкек</p><p>SPIN-код 7665-9251</p><p> </p></bio><bio xml:lang="en"><p>Bishkek</p></bio><email xlink:type="simple">guzyaliyaeldosm@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный центр кардиологии и терапии имени академика М.Миррахимова</institution></aff><aff xml:lang="en"><institution>National Center for Cardiology and Therapy named after Academician M. Mirrakhimov</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>17</day><month>04</month><year>2019</year></pub-date><volume>18</volume><issue>2</issue><fpage>26</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Норузбаева А.М., Курманбекова Б.Т., Османкулова Г.Э., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Норузбаева А.М., Курманбекова Б.Т., Османкулова Г.Э.</copyright-holder><copyright-holder xml:lang="en">Noruzbaeva A.M., Kurmanbekova B.T., Osmankulova G.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/776">https://cardiovascular.elpub.ru/jour/article/view/776</self-uri><abstract><sec><title>Цель</title><p>Цель. Выявить латентные нарушения углеводного обмена (НУО) во взаимосвязи с нейрогормональным статусом у госпитализированных больных с хронической сердечной недостаточностью (ХСН) ишемической этиологии</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Исследованы 174 больных c ХСН функционального класса II-IV (NYHA) ишемической этиологии, находящихся на одинаковой стандартной терапии ХСН (Р-адреноблокаторы, антагонисты минералокортикоидных рецепторов, ингибиторы ангиотензин-превращающего фермента, диуретики), без НУО и приема гипогликемических средств в анамнезе, проведены оральный тест толерантности к глюкозе и общеклиническое обследование. Содержание мозгового натрийуретического пропептида, альдостерона и инсулина определены методом иммуноферментного анализа. Инсулинорезистентность (ИР) оценена при помощи индекса HOMA-IR.</p></sec><sec><title>Результаты</title><p>Результаты. Среди 174 госпитализированных больных с ХСН II-IV функционального класса (NYHA) ишемической этиологии при помощи орального теста толерантности к глюкозе у 52,3% выявлены НУО: из них нарушенная толерантность к глюкозе (НТГ) — 33,9%, нарушенная гликемия натощак — 1,7% и сахарный диабет (СД) 2 типа впервые выявленный — 16,7%, у 47,7% пациентов НУО не обнаружены. У всех больных с ХСН наряду с повышением уровней мозгового натрийуретического пропептида и альдостерона, оказался повышенным и уровень инсулина. ИР возрастала по мере увеличения выраженности НУО (в группе без НУО — 10,78 (8,9-12,2), НТГ — 14,6 (11,2-18,2), СД 2 типа впервые выявленный — 18,6 (15,19-26,7), так же как и концентрация альдостерона оказалась выше в группе с СД 2 типа, в сравнении с группой НТГ (р2-3&lt;0,01).</p></sec><sec><title>Заключение</title><p>Заключение. Наличие и прогрессирование ИР у больных с ХСН ишемической этиологии во взаимосвязи с нейрогормональным статусом подчеркивает важность своевременного выявления латентных НУО с последующей их коррекцией.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To reveal latent disorders of carbohydrate metabolism (CHM) in conjunction with neurohormonal status in hospitalized patients with chronic heart failure (CHF) of ischemic etiology.</p></sec><sec><title>Material and methods</title><p>Material and methods. We analyzed 174 patients with NYHA class II-IV CHF of ischemic etiology who received the same standard CHF therapy (P-adrenergic blockers, mineralocorticoid receptor antagonists, angiotensin-converting enzyme inhibitors, diuretics), did not have disorders of CHM and never took hypoglycemic agent. We conducted oral glucose tolerance test (OGTT) and general clinical examination. The levels of brain natriuretic peptide, aldosterone and insulin was determined by enzyme immunoassay. Insulin resistance (IR) is assessed using the HOMA-IR index.</p></sec><sec><title>Results</title><p>Results. Among 174 hospitalized patients with NYHA class II-IV CHF of ischemic etiology disorders of CHM was detected in 52,3% of patients: 33,9% of those had impaired glucose tolerance (IGT), 1,7% — impaired fasting glucose (IFG), 16,7% — newly diagnosed type 2 diabetes mellitus (DM), in 47,7% of the patients disorders of CHM was not found. In all patients with CHF, along with elevated levels of brain natriuretic peptide and aldosterone, insulin levels were also increased. IR elevated with the increase in the severity of disorders of CHM (in the group without disorders of CHM — 10,78 (8,9-12,2), IGT — 14,6 (11,2-18,2), newly diagnosed type 2 DM — 18,6 (15,19-26,7). Also the concentration of aldosterone was higher in the group with DM, compared with the ITG group (p2-3&lt;0,01).</p></sec><sec><title>Conclusion</title><p>Conclusion. The presence and progression of IR in patients with CHF of ischemic etiology in conjunction with neurohormonal status emphasizes the importance of timely detection of latent CHM disorders with its future management.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>инсулинорезистентность</kwd><kwd>предиабет</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>коронарная болезнь сердца</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>insulin resistance</kwd><kwd>prediabetes</kwd><kwd>type 2 diabetes</kwd><kwd>coronary artery disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee D, Biggs ML, Mercer L, et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail. 2013;6(3):364-70. doi:10.1161/CIRCHEARTFAILURE.112.000022.</mixed-citation><mixed-citation xml:lang="en">Banerjee D, Biggs ML, Mercer L, et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail. 2013;6(3):364-70. doi:10.1161/CIRCHEARTFAILURE.112.000022.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Srinivasan MP, Kamath PK, Manjrekar PA, et al. Correlation of severity of coronary artery disease with insulin resistance. N Am J Med Sci. 2013;5(10):611-4. doi :10.4103/1947-2714.120799.</mixed-citation><mixed-citation xml:lang="en">Srinivasan MP, Kamath PK, Manjrekar PA, et al. Correlation of severity of coronary artery disease with insulin resistance. N Am J Med Sci. 2013;5(10):611-4. doi :10.4103/1947-2714.120799.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lopaschuk G, Ussher J, Folmes C, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207-58. doi:10.1152/physrev.00015.2009.</mixed-citation><mixed-citation xml:lang="en">Lopaschuk G, Ussher J, Folmes C, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207-58. doi:10.1152/physrev.00015.2009.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vardeny O, Sundstrom J, arnlov J, et al. Insulin resistance and incident heart failure: the ARIC study. JACC Heart Fail. 2013;1:531-6. doi: 10.1016/j.jchf.2013.07.006.</mixed-citation><mixed-citation xml:lang="en">Vardeny O, Sundstrom J, arnlov J, et al. Insulin resistance and incident heart failure: the ARIC study. JACC Heart Fail. 2013;1:531-6. doi: 10.1016/j.jchf.2013.07.006.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Selvaraj J, Sathish S, Mayilvahanan C, Balasubramanian K. Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Mol Cell Biochem. 2012 Sept;372(1-2):113-26. doi:10.1007/s11010-012-1452-2.</mixed-citation><mixed-citation xml:lang="en">Selvaraj J, Sathish S, Mayilvahanan C, Balasubramanian K. Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Mol Cell Biochem. 2012 Sept;372(1-2):113-26. doi:10.1007/s11010-012-1452-2.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-78. doi:10.1161/HYPERTENSIONAHA.111.190223.</mixed-citation><mixed-citation xml:lang="en">Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-78. doi:10.1161/HYPERTENSIONAHA.111.190223.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis andclassification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53. doi:10.1002/(SICI)1096-9136(199807)15:7&lt;539::AID-DIA668&gt;3.0.CO;2-S.</mixed-citation><mixed-citation xml:lang="en">Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis andclassification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53. doi:10.1002/(SICI)1096-9136(199807)15:7&lt;539::AID-DIA668&gt;3.0.CO;2-S.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Egstrup M, Schou M, Gustafsson I, et а!. Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail. 2011;13(3):319-26. doi:10.1093/eurjhf/hfq216.</mixed-citation><mixed-citation xml:lang="en">Egstrup M, Schou M, Gustafsson I, et а!. Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail. 2011;13(3):319-26. doi:10.1093/eurjhf/hfq216.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Circ Heart Fail. 2016;9:e002560. doi:10.1161/CIRCHEARTFAILURE.115.002560.</mixed-citation><mixed-citation xml:lang="en">Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Circ Heart Fail. 2016;9:e002560. doi:10.1161/CIRCHEARTFAILURE.115.002560.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-45. doi:10.1161/01.HYP.0000231338.41548.fc.</mixed-citation><mixed-citation xml:lang="en">Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-45. doi:10.1161/01.HYP.0000231338.41548.fc.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kumagai E, Adachi H, Jacobs DR, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension. 2011;58:1043-8. doi:10.1161/HYPERTENSIONAHA.111.180521.</mixed-citation><mixed-citation xml:lang="en">Kumagai E, Adachi H, Jacobs DR, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension. 2011;58:1043-8. doi:10.1161/HYPERTENSIONAHA.111.180521.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Huan Y, Deloach S, Keith SW, et al. Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans. J Am Soc Hypertens. 2012;6:56-65. doi:10.1016/j.jash.2011.09.005.</mixed-citation><mixed-citation xml:lang="en">Huan Y, Deloach S, Keith SW, et al. Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans. J Am Soc Hypertens. 2012;6:56-65. doi:10.1016/j.jash.2011.09.005.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Engelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation. 2007;116(9):984-92. doi:10.1161/CIRCULATIONAHA.107.708537.</mixed-citation><mixed-citation xml:lang="en">Engelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation. 2007;116(9):984-92. doi:10.1161/CIRCULATIONAHA.107.708537.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue Y, Kawai M, Minai K, et al. The impact of inverse correlation between N-terminal pro-B-type natriuretic peptide and insulin resistance in patients with heart failure. Metabolism. 2016;65(3):38-47. doi:10.1016/j.metabol.2015.09.019.</mixed-citation><mixed-citation xml:lang="en">Inoue Y, Kawai M, Minai K, et al. The impact of inverse correlation between N-terminal pro-B-type natriuretic peptide and insulin resistance in patients with heart failure. Metabolism. 2016;65(3):38-47. doi:10.1016/j.metabol.2015.09.019.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
